中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
z1期
33-36
,共4页
李大海%玛依努尔·尼亚孜
李大海%瑪依努爾·尼亞孜
리대해%마의노이·니아자
宫颈上皮内瘤变%人乳头瘤病毒%病毒载量%第二代杂交捕获法
宮頸上皮內瘤變%人乳頭瘤病毒%病毒載量%第二代雜交捕穫法
궁경상피내류변%인유두류병독%병독재량%제이대잡교포획법
Cervical interaepithelial neoplasia%Human papillomavirus%Viral load%Hybrid capture 2
目的 评价第二代杂交捕获(HC2)法检测高危型人乳头瘤病毒(HR-HPV)载量的临床应用价值.方法 2009年8月1日至2010年5月31日对就诊于新疆维吾尔自治区人民医院的2851例门诊或住院患者,接受HC2法检测HR-DNA,联合或未联合液基细胞学检查.二者中有任何一项阳性则行阴道镜检查并或活组织检查.结果 组织病理学诊断为慢性宫颈炎648例,CIN Ⅰ 150例,CINⅡ43例,CINⅢ64例,宫颈癌119例,炎症及阴性2475例,不同级别宫颈病变中HR-DNA阳性率为:炎症及阴性17.7％ (438/2475),CINⅠ 84.0％ (126/150), CINⅡ76.7％( 33/43), CINⅢ 81.3％(52/64),宫颈癌90.8％ (108/119),P＜0.05.HC2检测的HR-DNA病毒负荷载量在不同级别宫颈病变中分别为:慢性宫颈炎(223.60±476.55),CIN Ⅰ (448.38±758.86),CINⅡ(890.41±1036.29),CINⅢ(608.36±683.98),宫颈癌(1047.84±1008.43),P＜0.05.结论 病毒负荷量与宫颈癌前病变程度无关,但是病毒载量越高,宫颈病变程度越严重的可能性越大.HC2检测在宫颈癌前病变的筛查、管理和治疗后随访过程中有重要意义.
目的 評價第二代雜交捕穫(HC2)法檢測高危型人乳頭瘤病毒(HR-HPV)載量的臨床應用價值.方法 2009年8月1日至2010年5月31日對就診于新疆維吾爾自治區人民醫院的2851例門診或住院患者,接受HC2法檢測HR-DNA,聯閤或未聯閤液基細胞學檢查.二者中有任何一項暘性則行陰道鏡檢查併或活組織檢查.結果 組織病理學診斷為慢性宮頸炎648例,CIN Ⅰ 150例,CINⅡ43例,CINⅢ64例,宮頸癌119例,炎癥及陰性2475例,不同級彆宮頸病變中HR-DNA暘性率為:炎癥及陰性17.7％ (438/2475),CINⅠ 84.0％ (126/150), CINⅡ76.7％( 33/43), CINⅢ 81.3％(52/64),宮頸癌90.8％ (108/119),P＜0.05.HC2檢測的HR-DNA病毒負荷載量在不同級彆宮頸病變中分彆為:慢性宮頸炎(223.60±476.55),CIN Ⅰ (448.38±758.86),CINⅡ(890.41±1036.29),CINⅢ(608.36±683.98),宮頸癌(1047.84±1008.43),P＜0.05.結論 病毒負荷量與宮頸癌前病變程度無關,但是病毒載量越高,宮頸病變程度越嚴重的可能性越大.HC2檢測在宮頸癌前病變的篩查、管理和治療後隨訪過程中有重要意義.
목적 평개제이대잡교포획(HC2)법검측고위형인유두류병독(HR-HPV)재량적림상응용개치.방법 2009년8월1일지2010년5월31일대취진우신강유오이자치구인민의원적2851례문진혹주원환자,접수HC2법검측HR-DNA,연합혹미연합액기세포학검사.이자중유임하일항양성칙행음도경검사병혹활조직검사.결과 조직병이학진단위만성궁경염648례,CIN Ⅰ 150례,CINⅡ43례,CINⅢ64례,궁경암119례,염증급음성2475례,불동급별궁경병변중HR-DNA양성솔위:염증급음성17.7％ (438/2475),CINⅠ 84.0％ (126/150), CINⅡ76.7％( 33/43), CINⅢ 81.3％(52/64),궁경암90.8％ (108/119),P＜0.05.HC2검측적HR-DNA병독부하재량재불동급별궁경병변중분별위:만성궁경염(223.60±476.55),CIN Ⅰ (448.38±758.86),CINⅡ(890.41±1036.29),CINⅢ(608.36±683.98),궁경암(1047.84±1008.43),P＜0.05.결론 병독부하량여궁경암전병변정도무관,단시병독재량월고,궁경병변정도월엄중적가능성월대.HC2검측재궁경암전병변적사사、관리화치료후수방과정중유중요의의.
Objective To analyze clinical value of high risk human papillomavirus (HR-HPV) dose-effect in cervix tested by hybrid capture 2(HC2) and determine the relationship between HR-HPV virus load and cervical lesion.Methods From August 2009 to May 2010,2851women accepted HR-HPV test by HC2,with or without cytological test by TCT.All women with HR-HPV positive or abnormalities in cytology were taken cervical biopsy under the colposcopy.Results The diagnosis of histopathology were cervicitis in 648 cases,cervical intraepithelial neoplasia(CIN) Ⅰ 150 in cases,CIN Ⅱ 43 in cases,CIN Ⅲ 64 in cases and cervical cancer(CC) 119 in cases.The rate of HR-HPV infection was 17.7％ (438/2475) in healthy women and cervicitis,84.0％ ( 126/150 ) in CIN Ⅰ,76.7％ (33/43)in CINⅡ,81.3％ (52/64) in CINⅢ,90.8％ ( 108/119)in CC (P ＜0.05).The viral loads of HR-HPV DNA were 223.60 ±476.55 in cervicitis,448.38 ±758.86 in CIN Ⅰ,890.41±1036.29 in CIN Ⅱ,and 608.36 ±683.98 in CIN Ⅲ,1047.84 ± 1008.43 in CC ( P ＜ 0.05 ).Conclusion The viral loads of HR-HPV DNA have no correlation with the grade of cervical precancerous lesions,but the possibility of high-grade cervical intraepithelial neoplasia is higher with more viral loads.HC2 has a certain application value in screening and follow up of patients with cervical precancerous lesions or cervical cancer.
